Search

Your search keyword '"Jutel, M"' showing total 660 results

Search Constraints

Start Over You searched for: Author "Jutel, M" Remove constraint Author: "Jutel, M"
660 results on '"Jutel, M"'

Search Results

1. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study

2. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

3. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

4. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

6. Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma

7. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

9. From MASK-air® and SILAM to CATALYSE (Climate Action to Advance HeaLthY Societies in Europe)

13. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

14. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

15. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

16. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

17. The ARIA-MeDALL hypothesis

18. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

19. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products

22. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

23. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

24. AllergoOncology: Danger signals in Allergology and Oncology. A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

25. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app.

26. Climate change and global health: A call to more research and more action

27. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

29. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

30. Development and validation of combined symptom-medication scores for allergic rhinitis*

31. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

32. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data

33. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

34. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

35. Neuroprotective Natural Antibodies to Assemblies of Amyloidogenic Peptides Decrease with Normal Aging and Advancing Alzheimer's Disease

36. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

37. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

38. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

39. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

40. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

41. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

44. Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic – An EAACI Position Paper

45. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19

46. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper

47. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

48. Spices to Control COVID-19 Symptoms: Yes, but Not Only

49. EAACI Biologicals Guidelines—Recommendations for severe asthma

50. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus

Catalog

Books, media, physical & digital resources